## **REMARKS**

In response to the Restriction Requirement mailed April 23, 2003 (Paper No. 18), Applicants have elected Group III (claims 21-23) drawn to methods of identifying integrin mediated signaling by determining phosphorylation, classified in Class 435, subclass 7.1. In this response, Applicants have withdrawn claims 1-20 and 24-29 as being drawn to non-elected inventions, have amended claim 22 and have added new claims 24-40. Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups I-II and IV-V (claims 1-20 and 24-29) for later prosecution in this or subsequent applications. Support for the amendment and new claims can be found in the specification at, for example, page 37 line 10 through page 38 line 4, page 43 lines 13-17, and pages 28 line 17 through page 32 line 16. No new matter has been added.

This paper is being filed timely within the one month deadline for a response. No additional extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

22 May 2003

MILLENNIUM PHARMACEUTICALS, INC.

Ву

TracyM. Sioussat, Ph.D. Registration No. 50,609

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820